XML 56 R40.htm IDEA: XBRL DOCUMENT v2.4.0.6
Quarterly Financial Information (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]  
Schedule of quarterly financial information (unaudited)
The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2012 and 2011 (unaudited):
 
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
December 31,
2012
 
September 30,
2012
 
June 30,
2012
 
March 31,
2012
Consolidated Statements of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
License fee and milestone revenue
$
120,546

 
$
128,745

 
$
127,157

 
$
131,088

Revenue under collaborative research and development arrangements
36,233

 
116,234

 
—

 
—

Grants and miscellaneous revenue
977,974

 
609,717

 
308,925

 
1,562,033

Total revenues
1,134,753

 
854,696

 
436,082

 
1,693,121

Operating Expenses:
 
 
 
 
 
 
 
Research and development
4,442,841

 
4,972,319

 
4,527,086

 
4,042,579

General and administrative
2,919,000

 
2,674,362

 
2,696,909

 
2,488,088

Gain on sale of assets
—

 
(500,000
)
 
—

 
(651,000
)
Total operating expenses
7,361,841

 
7,146,681

 
7,223,995

 
5,879,667

Loss from operations
(6,227,088
)
 
(6,291,985
)
 
(6,787,913
)
 
(4,186,546
)
Interest and other income, net
56,520

 
37,013

 
41,036

 
31,544

Change in fair value of common stock warrants
3,049,649

 
(1,113,638
)
 
3,594,782

 
(3,548,173
)
Gain (Loss) from investment in affiliated entity
2,449,615

 
736,121

 
(992,373
)
 
(561,544
)
Net loss
(671,304
)
 
(6,632,489
)
 
(4,144,468
)
 
(8,264,719
)
Net loss attributable to non-controlling interest
12,553

 
10,413

 
11,289

 
9,770

Net loss attributable to Inovio Pharmaceuticals, Inc.
$
(658,751
)
 
$
(6,622,076
)
 
$
(4,133,179
)
 
$
(8,254,949
)
Loss per common share—basic and diluted:
 
 
 
 
 
 
 
Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders
$
—

 
$
(0.05
)
 
$
(0.03
)
 
$
(0.06
)
Weighted average number of common shares—basic and diluted
140,704,889

 
135,389,308

 
134,968,394

 
134,968,394



 
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
December 31,
2011
 
September 30,
2011
 
June 30,
2011
 
March 31,
2011
Consolidated Statements of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
License fee and milestone revenue
$
132,936

 
$
183,138

 
$
131,664

 
$
120,118

Grants and miscellaneous revenue
1,499,732

 
2,454,423

 
2,288,099

 
2,985,147

Total revenues
1,632,668

 
2,637,561

 
2,419,763

 
3,105,265

Operating Expenses:
 
 
 
 
 
 
 
Research and development
4,158,400

 
6,987,824

 
4,463,978

 
4,421,799

General and administrative
3,253,990

 
2,323,188

 
3,092,386

 
3,319,232

Gain on sale of assets
—

 
(337,000
)
 
—

 
(250,000
)
Total operating expenses
7,412,390

 
8,974,012

 
7,556,364

 
7,491,031

Loss from operations
(5,779,722
)
 
(6,336,451
)
 
(5,136,601
)
 
(4,385,766
)
Interest and other income, net
18,893

 
5,738

 
7,799

 
1,855

Change in fair value of common stock warrants
1,113,076

 
346,956

 
4,898,758

 
2,331,868

(Loss) Gain from investment in affiliated entity
(840,436
)
 
1,427,176

 
(2,607,227
)
 
(370,011
)
Net loss
(5,488,189
)
 
(4,556,581
)
 
(2,837,271
)
 
(2,422,054
)
Net loss attributable to non-controlling interest
11,948

 
14,649

 
15,112

 
9,441

Net loss attributable to Inovio Pharmaceuticals, Inc.
$
(5,476,241
)
 
$
(4,541,932
)
 
$
(2,822,159
)
 
$
(2,412,613
)
Loss per common share—basic and diluted:
 
 
 
 
 
 
 
Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders
$
(0.04
)
 
$
(0.04
)
 
$
(0.02
)
 
$
(0.02
)
Weighted average number of common shares—basic and diluted
129,382,305

 
127,256,907

 
127,256,364

 
120,922,577